CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator
08-03-2022 – After five years, the project denovoSkin successfully exits the Wyss Zurich Translational Center. With the transfer of technology from the Wyss Zurich Regenerative Medicine Technologies Platform and the start of its onsite production facilities at its Headquarters in Schlieren, the start-up CUTISS achieves full independence in producing denovoSkin for current and future clinical trials and patients on compassionate basis.
Until now, CUTISS’s products were manufactured at the GMP facility of Wyss Zurich Regenerative Medicine Technologies Platform, University of Zurich. Following the successful transfer of technology, CUTISS has become one of the first regenerative medicine companies to transfer out of this platform at Wyss Zurich.
